Rystiggo
(Rozanolixizumab)
Provider Summary
Primary Uses
Generalized myasthenia gravis (AChR+ or MuSK+ per label).
Mechanism of action
FcRn blocker that reduces circulating IgG (including pathogenic autoantibodies) by increasing IgG catabolism.
Pre-treatment / baseline requirements
Confirm diagnosis and antibody status; screen for active infection; review immunization status; baseline CBC/CMP per clinician; counsel on headache and infection risk.
Common side effects
Headache, infections, diarrhea, pyrexia (fever), hypersensitivity reactions, nausea
Serious adverse effects / key risks
Serious infections; hypersensitivity reactions; other risks per PI.
Referral requirements
Standard infusion referral form + drug-specific checklist
Patient & Caregiver Education
What it treats
Generalized myasthenia gravis (AChR+ or MuSK+)
How it works
Lowers certain antibodies (IgG) by blocking the FcRn pathway.
Before treatment
Tell your clinician if you have an active infection/fever, are pregnant/planning pregnancy, or have major heart/nerve problems. Depending on the medication, you may need labs or screening tests (e.g., TB/hepatitis) and a vaccine review.
Common side effects
Headache, infections, diarrhea, pyrexia, hypersensitivity reactions, nausea.
Get urgent help for
Serious infections; hypersensitivity reactions; other risks per PI.
On treatment day
Plan to stay for monitoring. If you feel dizzy, drowsy, or unwell afterward, do not drive and follow your clinician’s instructions.